Skip to main content
. 2020 Oct 26;12(1):197–209. doi: 10.1007/s13300-020-00945-4

Table 5.

Proportion of patients in the BOT group receiving a specific combination of oral antidiabetic drugs + basal insulin therapy or IDegLira

Therapeutic regimen Previous therapy (n = 186) Baseline visit (n = 186) 6-month follow-up (n = 157) 12-month follow-up (n = 51)
Basal insulin only 3.8% 3.2% 4.5%
Basal insulin + 1 OAD 33.3% 57.0% 66.2% 72.5%
Basal insulin + 2 OAD 52.7% 37.1% 26.8% 27.5%
Basal insulin + 3 OAD 9.7% 2.7% 2.5%
Basal insulin + 4 OAD 0.5%